Advanced search
Publication Cover
International Journal of Nanomedicine Volume 7, 2012 - Issue
Submit an article Journal homepage
156
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance

Yanyan Ren1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing;2 State Key Laboratory of Bioelectronics, Southeast University, Nanjing, People’s Republic of China
,
Haijun Zhang1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing;2 State Key Laboratory of Bioelectronics, Southeast University, Nanjing, People’s Republic of China
,
Baoan Chen1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, NanjingCorrespondence[email protected]
,
Jian Cheng1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Xiaohui Cai1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Ran Liu1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Guohua Xia1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Weiwei Wu1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Shuai Wang1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Jiahua Ding1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Chong Gao1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Jun Wang1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Wen Bao1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Lei Wang1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Liang Tian1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
,
Huihui Song1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing
&
Xuemei Wang1 Department of Hematology and Oncology, Key Medical Discipline, Jiangsu Province, Zhongda Hospital, and Faculty of Oncology, Medical School, Nanjing;2 State Key Laboratory of Bioelectronics, Southeast University, Nanjing, People’s Republic of China
 show all
Pages 2261-2269 | Published online: 03 May 2012

Figures & data

Figure 1 (A) Image of oleic acid-Pluronic-modified iron oxide nanoparticles (Fe3O4-MNP) under transmission electronic microscopy. (B) Size distribution histogram of Fe3O4-MNP.

Abbreviation: Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Figure 1 (A) Image of oleic acid-Pluronic-modified iron oxide nanoparticles (Fe3O4-MNP) under transmission electronic microscopy. (B) Size distribution histogram of Fe3O4-MNP.Abbreviation: Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Table 1 Temperature change of tumor site after treatment for different times (mean ± SD)

Figure 2 Appearance of tumor body in tumor-bearing nude mice at day 12 after treatment.

Notes: (1) Controls, (2) DNR, (3) DNR and 5-BrTet, (4) Fe3O4-MNP, and (5) Fe3O4-MNP-DNR-5-BrTet.

Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Figure 2 Appearance of tumor body in tumor-bearing nude mice at day 12 after treatment.Notes: (1) Controls, (2) DNR, (3) DNR and 5-BrTet, (4) Fe3O4-MNP, and (5) Fe3O4-MNP-DNR-5-BrTet.Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Figure 3 Relative tumor volume of mice after treatment for 12 days.

Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Figure 3 Relative tumor volume of mice after treatment for 12 days.Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Figure 4 Tumor inhibition rate of mice at day 4 after treatment.

Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Figure 4 Tumor inhibition rate of mice at day 4 after treatment.Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4-MNP, magnetic nanoparticles of Fe3O4.

Figure 5 Histopathologic examinations of K562/A02 tumors at day 12 after treatment (hematoxylin-eosin staining, 400×). (A) control, (B) DNR, (C) DNR and 5-BrTet, (D) Fe3O4-MNP, and (E) Fe3O4-MNP-DNR-5-BrTet.

Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4,-MNP, magnetic nanoparticles of Fe3O4.

Figure 5 Histopathologic examinations of K562/A02 tumors at day 12 after treatment (hematoxylin-eosin staining, 400×). (A) control, (B) DNR, (C) DNR and 5-BrTet, (D) Fe3O4-MNP, and (E) Fe3O4-MNP-DNR-5-BrTet.Abbreviations: DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; Fe3O4,-MNP, magnetic nanoparticles of Fe3O4.

Figure 6 Expression of P-glycoprotein and apoptosis-related protein after treatment.

Notes: (1) Control, (2) DNR, (3) DNR and 5-BrTet, (4) Fe3O4-MNP, and (5) Fe3O4-MNP-DNR-5-BrTet.

Abbreviations: P-gp, P-glycoprotein; DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; MNP-Fe3O4, magnetic nanoparticles of Fe3O4.

Figure 6 Expression of P-glycoprotein and apoptosis-related protein after treatment.Notes: (1) Control, (2) DNR, (3) DNR and 5-BrTet, (4) Fe3O4-MNP, and (5) Fe3O4-MNP-DNR-5-BrTet.Abbreviations: P-gp, P-glycoprotein; DNR, daunorubicin; 5-BrTet, 5-bromotetrandrine; MNP-Fe3O4, magnetic nanoparticles of Fe3O4.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.